A bipartisan bill known as the Biotech Investment National Security Act (BINSA) was introduced to broaden federal oversight of common biotechnology activities. According to the publicly available portion of the STAT opinion, the scope described by sponsors includes pharmaceutical development, biologics manufacturing, and clinical research and development (R&D). The sponsors frame the measure as necessary to protect U.S. national security interests tied to medical research and innovation.
The accessible text presents BINSA as an add-on to earlier restrictions and as part of a broader U.S. policy effort to limit the offshoring of strategic biotech capabilities. The authors warn this legislative push could substantially reconfigure where and how global drug development occurs.
BINSA was introduced following passage of or proposals in the same policy space, notably the Comprehensive Outbound Investment National Security (COINS) Act filed in December 2025. The STAT excerpt links BINSA to geopolitical concerns about technology transfer and foreign access to U.S. biotech know-how.
The bill’s public rollout referenced as motivation two large R&D and licensing agreements that U.S. pharmaceutical companies — named in the excerpt as Pfizer and Bristol Myers Squibb — signed with Chinese biopharma firms. In comments cited by the STAT piece, Rep. John Moolenaar criticized such deals as threatening American pharmaceutical production.
The authors of the STAT opinion raise a key concern: BINSA, as drafted or described in the accessible text, could create a path for companies to circumvent U.S. restrictions by relocating or reclassifying activities geographically — an effect the authors call “Eurowashing.”
In this framing, Eurowashing would occur if firms respond to U.S. export or investment limits by shifting operations, trials, partnerships, or legal entities to Europe or other jurisdictions that are not covered by BINSA, while preserving commercial ties to Chinese partners. The article suggests this could leave the U.S. less protected than sponsors intend, because the control point of sensitive activity would move outside U.S. jurisdiction rather than being severed.
The publicly available excerpt does not include the legislative language of BINSA, specific mechanisms that would enable Eurowashing, or documented examples of companies pursuing such a route. Those details appear in the portion of the STAT article behind the STAT+ paywall and therefore were not reported in the source text provided here.
Based on the accessible commentary, the authors argue BINSA could reshuffle global drug development by motivating companies to relocate certain activities to jurisdictions not targeted by the law. That geographic reallocation could produce several effects noted or implied in the excerpt:
Reduced onshore clinical R&D and manufacturing investment in the United States if firms seek to avoid restrictions.
Acceleration of R&D activity in non-U.S. hubs — potentially benefiting European centers or other third-party countries that do not fall under BINSA’s enforcement.
Complex compliance and transaction structuring by companies attempting to balance access to global partners with adherence to U.S. restrictions.
A potential mismatch between the bill’s security goals and its real-world impact if enforcement and definitions of covered activities leave loopholes.
The STAT excerpt frames these developments as significant because they could mean the largest beneficiaries of the policy are not American firms or U.S. research infrastructure, but instead actors and jurisdictions positioned to capture relocated activity.
The portion of the STAT opinion available in the source is explicit that the full analysis is exclusive to STAT+ subscribers. As a result, several critical items are not reported in the accessible text and cannot be inferred without risking fabrication. These missing details include but may not be limited to:
Exact statutory language or key provisions of BINSA that would determine covered activities, enforcement mechanisms, thresholds, or penalties.
Concrete examples, case studies, or empirical data demonstrating how companies might execute Eurowashing in practice.
The authors’ specific policy recommendations or proposed fixes to close the identified loophole.
Any supporting evidence, such as transaction structures used by companies, timelines, or legislative amendments under consideration.
Full attribution of claims, detailed quotes beyond the brief citation of Rep. John Moolenaar, or additional stakeholder perspectives cited later in the piece.
Because those elements were not reported in the source material provided, this rewrite refrains from adding or inventing factual specifics. Readers seeking a complete account, legislative text, or the authors’ full argument should consult the original, full STAT+ article.
The available STAT excerpt summarizes a provocative argument: BINSA aims to expand U.S. oversight of biotech to protect national security, but as described in the public portion of the opinion, it may include a design weakness that allows firms to route activity outside U.S. jurisdiction — a phenomenon the authors call Eurowashing. The full scope of that risk, the bill’s precise provisions, and proposed remedies were not included in the paywalled text and therefore are not reported here.
For a complete review of the legislative language, detailed examples, and the authors’ recommended policy changes, consult the full STAT article or the BINSA bill text directly.